

# Laurence Albiges

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5140592/laurence-albiges-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166  
papers

9,912  
citations

41  
h-index

99  
g-index

186  
ext. papers

13,762  
ext. citations

7.3  
avg, IF

5.9  
L-index

#	Paper	IF	Citations
166	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , <b>2018</b> , 359, 91-97	33.3	2203
165	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1103-1115	59.2	1069
164	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17009	51.1	963
163	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753
162	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 417-427	59.2	416
161	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. <i>European Urology</i> , <b>2016</b> , 70, 256-62	10.2	234
160	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1158-64	12.5	205
159	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , <b>2016</b> , 69, 866-74	10.2	199
158	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5461-5471	12.9	158
157	Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1216-25	12.9	153
156	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2445-2452	12.9	150
155	Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 482-7	2.2	133
154	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. <i>European Urology</i> , <b>2015</b> , 68, 228-35	10.2	127
153	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , <b>2019</b> , 76, 151-156	10.2	125
152	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2993-3001	2.2	112
151	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3655-3663	2.2	111
150	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , <b>2020</b> , 5, e001079 <sup>6</sup>		109

149	MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3411-21	12.9	108
148	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. <i>European Urology</i> , <b>2015</b> , 67, 100-110	10.2	106
147	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , <b>2018</b> , 73, 311-315	10.2	104
146	A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , <b>2017</b> , 71, 426-436	10.2	89
145	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , <b>2020</b> , 26, 1733-1741	50.5	85
144	Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. <i>European Urology</i> , <b>2016</b> , 70, 623-632	10.2	83
143	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>European Urology</i> , <b>2019</b> , 75, 111-128	10.2	82
142	Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2008-2016	2.2	74
141	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 147-163	7.5	74
140	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2019</b> , 108, 33-40	7.5	71
139	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2580-6	7.5	69
138	High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2570-7	7.5	58
137	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. <i>Nature Cancer</i> , <b>2020</b> , 1, 965-975	15.4	58
136	Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. <i>European Urology</i> , <b>2014</b> , 65, 713-20	10.2	54
135	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , <b>2017</b> , 20, 205-215	10.6	52
134	Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma. <i>European Urology</i> , <b>2017</b> , 71, 719-722	10.2	52
133	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1247-1255	13.4	51
132	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1946-52	7.5	49

131	Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920907504	5.4	48
130	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , <b>2018</b> , 74, 805-809	10.2	47
129	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 226-235	7.5	45
128	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , <b>2017</b> , 22, 286-292	5.7	44
127	Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2016</b> , 4, 12-7	12.5	42
126	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. <i>European Urology</i> , <b>2021</b> , 79, 339-342	10.2	42
125	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , <b>2018</b> , 78, 1443-1457	11.1	41
124	Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2011</b> , 25, 813-33	3.1	40
123	Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. <i>Drugs</i> , <b>2020</b> , 80, 1169-1181	11.1	38
122	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , <b>2015</b> , 68, 154-60	10.2	37
121	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , <b>2019</b> , 2, 505-514	6.7	35
120	Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients <b>2017</b> , 5, 31		35
119	Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4508-4508	2.2	32
118	Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. <i>European Journal of Cancer</i> , <b>2018</b> , 98, 38-47	7.5	29
117	Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. <i>European Journal of Cancer</i> , <b>2016</b> , 61, 44-51	7.5	29
116	Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018792531		31
115	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.. <i>European Urology</i> , <b>2022</b> ,	10.2	29
114	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , <b>2017</b> , 72, 974-983	10.2	27

113	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 820-4	7.3	26
112	Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4064-4075	2.2	25
111	Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines Panel. <i>European Urology Oncology</i> , <b>2020</b> , 3, 57-72	6.7	23
110	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e981-e994	3.3	22
109	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , <b>2016</b> , 69, 151-157	7.5	21
108	Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 202.e9-17	2.8	19
107	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial. <i>European Journal of Cancer</i> , <b>2020</b> , 129, 107-116	7.5	19
106	Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 185-192	7.5	18
105	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , <b>2020</b> , 77, 761-763	10.2	18
104	Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: results of a pooled analysis of non-interventional studies. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2368-74	7.5	17
103	A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS767-TPS767	2.2	17
102	Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4569-4569	2.2	15
101	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 898-904	8.7	14
100	Compliance with guidelines and correlation with outcome in patients with advanced germ-cell tumours. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1284-90	7.5	14
99	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 120, 120-126	7	14
98	Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. <i>European Journal of Cancer</i> , <b>2021</b> , 142, 102-111	7.5	14
97	Cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2499-2504	4	13
96	Imaging in Suspected Renal-Cell Carcinoma: Systematic Review. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e345-e355	3.3	13

95	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 55, 211-217	14.4	13
94	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 403-410.e2	3.3	12
93	Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 140-140	2.2	12
92	Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 542-542	2.2	12
91	Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study. <i>BJU International</i> , <b>2019</b> , 123, 804-810	5.6	12
90	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , <b>2017</b> , 80, 55-62	7.5	11
89	Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1033	5.3	11
88	Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?. <i>Oncologist</i> , <b>2012</b> , 17, 1051-62	5.7	11
87	Axitinib in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 499-507	3.5	10
86	Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5534-5542	12.9	10
85	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. <i>European Journal of Cancer</i> , <b>2020</b> , 136, 76-83	7.5	9
84	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , <b>2020</b> , 3, 433-452	6.7	9
83	Tumor burden as an independent prognostic factor in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 397-397	2.2	9
82	Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4563-4563	2.2	8
81	Treating patients with renal cell carcinoma and bone metastases. <i>Expert Review of Anticancer Therapy</i> , <b>2018</b> , 18, 1135-1143	3.5	8
80	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 123-132	7.5	8
79	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , <b>2021</b> , 108, 106482	2.3	8
78	Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 432-438	7.3	7

77	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , <b>2020</b> , 129, 117-122	7.5	6
76	Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. <i>Cancer Cell International</i> , <b>2014</b> , 14, 4	6.4	6
75	Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e1081-e1088	3.3	6
74	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma Results of a phase III noninferiority trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, LBA3-LBA3	2.2	6
73	NIVOREN GETUG-AFU 26 translational study: Association of PD-1, AXL, and PBRM-1 with outcomes in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 618-618	2.2	6
72	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , <b>2021</b> ,	13.4	6
71	Characterization of Testicular Masses in Adults: Performance of Combined Quantitative Shear Wave Elastography and Conventional Ultrasound. <i>Ultrasound in Medicine and Biology</i> , <b>2019</b> , 45, 720-731	3.5	6
70	A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation. <i>Angiogenesis</i> , <b>2019</b> , 22, 383-395	10.6	5
69	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , <b>2021</b> , 4, 274-281	6.7	5
68	Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 310-310	2.2	5
67	Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. <i>European Urology</i> , <b>2021</b> , 80, 325-329	10.2	5
66	Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 82-84	19.4	4
65	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.. <i>European Urology</i> , <b>2021</b> ,	10.2	4
64	CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma.. <i>Future Oncology</i> , <b>2021</b> ,	3.6	4
63	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5002-5002	2.2	4
62	Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 699-699	2.2	4
61	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , <b>2021</b> , 81, 266-266	10.2	4
60	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4

59	Current and future strategies in nonclear-cell metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , <b>2015</b> , 25, 367-73	2.8	3
58	Brain metastases (BM) from renal cell carcinoma treated with nivolumab: Evidence of early brain flare?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 520-520	2.2	3
57	Gut microbiome composition to predict resistance in renal cell carcinoma (RCC) patients on nivolumab.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4519-4519	2.2	3
56	Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 582-582	2.2	3
55	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19321-e19321	2.2	3
54	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 670827	8.4	3
53	Association of thrombotic microangiopathy with atezolizumab therapy in cancer patients. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 34-36	7.5	3
52	Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, 444-451	3.3	3
51	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , <b>2021</b> , 26, 389-396	5.7	3
50	Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 301-301	2.2	3
49	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. <i>European Urology</i> , <b>2018</b> , 74, 849-851	10.2	3
48	Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights. <i>European Urology Oncology</i> , <b>2021</b> ,	6.7	3
47	Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?. <i>European Urology Oncology</i> , <b>2021</b> , 4, 843-850	6.7	2
46	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , <b>2020</b> , 11, 4582-4592	3.3	2
45	Effect of immunotherapy (IO) on primary renal tumor in metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 649-649	2.2	2
44	Systematic Screening of COVID-19 Disease Based on Chest CT and RT-PCR for Cancer Patients Undergoing Radiation Therapy in a Coronavirus French Hotspot. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 947-956	4	2
43	Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. <i>European Journal of Cancer</i> , <b>2021</b> , 151, 106-114	7.5	2
42	Impact of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2 overexpressing breast carcinomas.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 601-601	2.2	1



41	Metastatic chromophobe renal cell carcinoma treated with target therapies: A Renal Cross Chanel Group (RCCG) study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4561-4561	2.2	1
40	Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4564-4564	2.2	1
39	Prognosis of brain metastasis (BM) in metastatic renal cell carcinoma (mRCC): Experience from Gustave Roussy (IGR).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4561-4561	2.2	1
38	Stereotactic radiotherapy (SRT) for oligometastatic (OM) relapse and metastatic oligoprogression (OP) in renal cell carcinoma (RCC) patients (pts): A study of the GETUG group.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16105-e16105	2.2	1
37	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23221-e23221	2.2	1
36	Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 707-707	2.2	1
35	Validation of the lung immune prognostic index (LIPI) in patients with metastatic renal cell carcinoma treated with nivolumab in the GETUG-AFU 26 NIVOREN trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 735-735	2.2	1
34	CaboPoint, a phase II, open-label study of cabozantinib as second-line therapy for patients with clear cell metastatic renal cell carcinoma (RCC), whose disease progressed after therapy with checkpoint inhibitors (CPIs).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS772-TPS772	2.2	1
33	Is body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 630-630	2.2	1
32	Prospective observational study on pazopanib in patients treated for advanced/metastatic renal cell carcinoma (RCC): APOLON Study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 629-629	2.2	1
31	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4521-4521	2.2	1
30	Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e91-3	3.3	1
29	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. <i>Clinical Genitourinary Cancer</i> , <b>2021</b> , 19, 167-175	3.3	1
28	REchallenge of NIVOLUMAB (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.. <i>Journal of Oncology</i> , <b>2022</b> , 2022, 3449660	4.5	1
27	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101806	2.2	1
26	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
25	Effect of nivolumab on tumor growth rate (TGR) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 481-481	2.2	0
24	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , <b>2021</b> , 158, 1-11	7.5	0

23	Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 683-683	2.2	○
22	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , <b>2021</b> , 39, 1039-1041	24.3	○
21	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101090	2.2	○
20	PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.. <i>Drugs</i> , <b>2022</b> , 1	12.1	○
19	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study <b>2022</b> , 10, e004885		○
18	A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, e485-e487	3.3	
17	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 754-754	2.2	
16	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 701-701	2.2	
15	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , <b>2021</b> , 1-6	3.2	
14	Are patients ready to participate in diet intervention trials in oncology? Experience from renal cell carcinoma (RCC) patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 628-628	2.2	
13	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS3159-TPS3159	2.2	
12	Sunlight and testicular germ cell tumor rates in the USA.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15565-e15565		
11	Melanoma risk in men with testicular germ cell tumors in the United States.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15554-e15554	2.2	
10	Disease burden and outcome in metastatic hormone sensitive prostate cancer (mHSPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5052-5052	2.2	
9	A new prognostic model of survival in second-line targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16113-e16113	2.2	
8	Prognostic role of body composition parameters in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4621-4621	2.2	
7	Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 392-392	2.2	
6	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 448-448	2.2	

- 5 Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. *BJU International*, **2021**, 128, 254-261 5.6
- 4 Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivorentETUG AFU 26 trial.. *Journal of Clinical Oncology*, **2021**, 39, 359-359 2.2
- 3 Association of cabozantinib residual concentration (C<sub>trough</sub>) and blood clearance (Cl/F) with toxicity (tox) and progressive disease (PD) in metastatic renal cell carcinoma (mRCC) patients (pts): Results from a monocentric pharmacokinetics (PK) study.. *Journal of Clinical Oncology*, **2021**, 39, 292-292 2.2
- 2 Safety and efficacy of nivolumab in older patients (pts) with renal cell carcinoma: Results of a sub-group analysis of the GETUG-AFU 26 NIVOREN multicenter phase II study.. *Journal of Clinical Oncology*, **2021**, 39, 331-331 2.2
- 1 Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. *European Journal of Cancer*, **2022**, 170, 158-168 7.5